Experimental Medicine Incubator
Experimental medicine is vital to early-stage drug discovery, addressing fundamental questions in research through pioneering in-human studies using techniques such as medical imaging.
DPUK's Experimental Medicine Incubator powers clinical research that aims to reduce the time, cost and risk of drug development.
Our programmes increase industry confidence in the decisions to pursue or cancel potential treatments based on early indications of their effect on disease processes in people with, or at risk of, dementia.
How it works
The Experimental Medicine Incubator works closely with DPUK's other workstreams – the DPUK Data Portal and the Trials Delivery Framework – to generate research ideas, to share new results, and to recruit the best volunteers to studies and trials.
Academic researchers work in tandem with industry scientists to make sure pharmaceutical companies and universities have the most up-to-date information – such as helpful new biomarkers or candidates for drug repurposing – in the development of new treatments for dementia.
Themes and research projects
Our experimental medicine studies are grouped around three core processes in Alzheimer's disease and other dementias: the loss of synapses, brain inflammation, and vascular disease. Use the links below to visit our theme webpages and find out more about individual studies.
Major research studies
The Deep and Frequent Phenotyping study is the world's most in-depth study of its kind into the early signs of Alzheimer's disease.
The New Therapeutics in Alzheimer's Disease study is helping to detect subtle changes in the brain associated with the onset of Alzheimer's disease.
For further information, or to express an interest in becoming involved as a collaborator in DPUK's experimental medicine programme, please contact Dr Haddy Fye, Project Manager in DPUK's Cambridge-based team.